Dimitri E. Grigoriadis Sells 71,775 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Dimitri E. Grigoriadis sold 71,775 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $77.98, for a total transaction of $5,597,014.50. Following the sale, the insider now directly owns 154,717 shares in the company, valued at approximately $12,064,831.66. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) traded up $1.52 on Tuesday, reaching $83.69. 778,785 shares of the company’s stock traded hands, compared to its average volume of 1,026,033. Neurocrine Biosciences, Inc. has a 52 week low of $39.21 and a 52 week high of $91.82. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. The firm has a market cap of $7,330.00, a PE ratio of -37.70, a PEG ratio of 13.14 and a beta of 0.26.

A number of institutional investors and hedge funds have recently made changes to their positions in NBIX. The Manufacturers Life Insurance Company raised its holdings in shares of Neurocrine Biosciences by 7.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after acquiring an additional 193 shares during the period. State Board of Administration of Florida Retirement System raised its holdings in shares of Neurocrine Biosciences by 0.7% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock worth $7,380,000 after acquiring an additional 810 shares during the period. Amalgamated Bank raised its holdings in shares of Neurocrine Biosciences by 5.7% during the 4th quarter. Amalgamated Bank now owns 17,484 shares of the company’s stock worth $1,357,000 after acquiring an additional 947 shares during the period. Mutual of America Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 0.9% during the 3rd quarter. Mutual of America Capital Management LLC now owns 112,862 shares of the company’s stock worth $6,916,000 after acquiring an additional 1,036 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Neurocrine Biosciences by 25.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,904 shares of the company’s stock worth $458,000 after acquiring an additional 1,200 shares during the period.

A number of research firms recently issued reports on NBIX. BidaskClub raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 31st. Needham & Company LLC lifted their price target on shares of Neurocrine Biosciences to $95.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. Oppenheimer set a $95.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research note on Monday, January 15th. Jefferies Group lifted their price target on shares of Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a research note on Friday, January 5th. Finally, Robert W. Baird reissued a “buy” rating and issued a $84.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. One investment analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $84.13.

TRADEMARK VIOLATION NOTICE: This story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/13/dimitri-e-grigoriadis-sells-71775-shares-of-neurocrine-biosciences-inc-nbix-stock.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply